Clinical Trial News

Subcutaneous rituximab showed similar efficacy and safety to intravenous rituximab in non-Hodgkin lymphoma, with lower costs and shorter administration times. Education and training are crucial for increasing subcutaneous rituximab use.

Donor human milk reduces NEC risk by about half in very preterm or VLBW infants, with little to no effect on late-onset invasive infection or all-cause mortality.

Alfehaid et al. analyzed colchicine-related drug-drug interactions (DDIs) in COVID-19 patients, finding no increased risk of adverse events from potential DDIs. The study highlights the need for efficient screening and testing of DDIs using big data and clinical trial repurposing, emphasizing the importance of conservative prescribing and interaction checkers in clinical practice.

AcuraStem received a $4 million grant from CIRM to advance its UNC13A program targeting ALS and FTD, using the iNeuroRx platform to develop antisense oligonucleotides that restore normal function disrupted by TDP-43 pathology.

Immediate change: card charged prorated amount based on current subscription level. Options: OK or Cancel.

Robin Dobbins, an oncology research nurse at Georgia Cancer Center, manages pediatric immunotherapy trials, supporting kids with relapsed brain tumors. Despite initial reluctance, she finds fulfillment in her role, connecting with families and contributing to ALSF-funded research, aiming for a Phase 3 trial.

Healthy adults with BMI < 45 kg/m2, no diabetes, heart, or kidney issues can participate. Study includes meals, treadmill exercise, glucose test, blood/urine samples, and genetic info collection. $300 compensation. Meals provided. Contact: genesis@uabmc.edu or (205) 975-3956.

Lundbeck starts phase I study with second-generation migraine drug Lu AG09222 for potential combination treatment in migraine prevention, as per Clinical Trials registration.

Robin Love's participation in a clinical trial at The University of Kansas Cancer Center 18 years ago led to significant advancements in breast cancer treatment. Dr. Carol Fabian highlights the progress in understanding breast cancer as multiple diseases, with 70-80% responding well to treatment. Love's HER2-positive breast cancer, once aggressive, is now survivable, inspiring her son to become a doctor. Fabian emphasizes the importance of clinical trials and precision medicine in improving survivorship and early detection.

FDA reviewers express concerns over the benefits vs. risks of sulopenem etzadroxil/probenecid, a novel oral antibiotic for uncomplicated urinary tract infections (uUTIs), ahead of an advisory committee meeting. The drug, with activity against gram-positive, gram-negative, and anaerobic organisms, was rejected in 2021 but resubmitted by Iterum Therapeutics in April after another phase III trial. The new trial data showed non-inferiority to amoxicillin/clavulanate but had a small sample size of resistant organisms, raising efficacy questions. The FDA warns of potential inappropriate use and antimicrobial resistance (AMR) risks, emphasizing the need for careful stewardship and guideline considerations.